CRP and rheumatoid arthritis: When given as monotherapy in RA patients with uncontrolled disease despite the use of at least 1 cDMARD, decernotinib, at dosages of 25 mg, 50 mg, 100 mg, or 150 mg twice a day, led to a significant improvement in the ACR20 response and DAS28-CRP scores at week 12 compared to placebo.